Comparative evaluation of intralesional triamcinolone and hyaluronidase versus platelet rich fibrin iPRF and hyaluronidase in the treatment of grade II and grade III oral submucous fibrosis a randomized clinical trial

This study is a prospective randomized split-mouth clinical trial designed to evaluate and compare the clinical efficacy of two intralesional treatment modalities in the management of Oral Submucous Fibrosis (OSMF).

A total of 20 patients diagnosed with Grade II and Grade III OSMF were included. In each patient, both treatment modalities were administered on opposite sides of the buccal mucosa, allowing intra-individual comparison. The interventions included:

• Injectable Platelet-Rich Fibrin (iPRF) with Hyaluronidase (test side)
• Triamcinolone Acetonide with Hyaluronidase (control side)

Treatment was carried out over 10 bi-weekly sessions, with regular follow-up assessments.

The primary clinical parameters evaluated were:

• Burning sensation (VAS)
• Pain during mouth opening (VAS)
• Cheek flexibility (measured in cm)
• Maximum mouth opening (interincisal distance)

The study aimed to determine whether iPRF, a regenerative therapy, provides superior clinical outcomes compared to conventional corticosteroid therapy, particularly in terms of symptomatic relief and functional improvement.

Statistical analysis was performed using paired comparisons and repeated measures ANOVA to assess intra-group and inter-group differences.